Hookworm

From 2000 to 2017 the Sabin Vaccine Institute partnered with the Texas Children’s Hospital Center for Vaccine Development at Baylor College of Medicine in Houston, Texas to develop safe, effective and low-cost vaccines for infectious and neglected tropical diseases. Baylor College of Medicine and Texas Children’s Hospital Center for Vaccine Development continue this research as of May 2017.

Past Work

For more than a decade, the Sabin PDP collaborated with partners from across the globe to develop new, low-cost vaccines that have little commercial market for diseases that primarily impact the world's poorest populations, including humanhookworm, schistosomiasis, onchocerciasis, SARS and Chagas disease. Baylor College of Medicine and Texas Children’s Hospital Center for Vaccine Development continue this research as of May 2017.

Neglected tropical diseases (NTDs) are the most common affliction of the world’s poorest people. Thriving in communities that lack access to health services, adequate sanitation and clean water, NTDs blind, disable and disfigure, trapping families in a cycle of poverty and disease.

These Blood Suckers Cost $2.5 Billion to $138 Billion Each Year

Three guesses on which blood suckers are costing the world somewhere between $2.5 billion to $138 billion each year. Vampires? Well, the Twilight novel and movie series portrays vampires as a bit more “emo” and “preppy” than vicious. How about vampires? No, there have been limited vampire economic studies. Vampires? No, repeating the same guess won’t make it correct.
Forbes
During my many years as a diplomat, I saw firsthand how the power of collective action can be extraordinarily important in shaping momentous changes. A few examples include: the creation of the PEPFAR program to combat HIV/AIDS, the accelerated response to terrorism following the East African embassy bombings, effective international coordination to tackle the SARS and avian flu threats, and the constructive collaboration between the United States and Vietnam on the issue of Agent Orange.

Last year, the leaders of some of the wealthiest nations pledged help control and eliminate the most common neglected tropical diseases (NTDs) by 2020.

Sabin PDP Begins Phase 1 Clinical Trial to Co-Administer Two Novel Hookworm Vaccine Candidates in Brazil

WASHINGTON, D.C. — April 28, 2016 — The Sabin Vaccine Institute (Sabin) today announced that its Product Development Partnership (Sabin PDP) began a Phase 1 clinical trial of Na-APR-1 (M74)/Alhydrogel® co-administered with Na-GST-1/Alhydrogel in Brazilian adults.

This article was originally posted on the DSW Blog.

Pages

Subscribe to RSS - Hookworm